title: Influence of preservation solution on human islet isolation outcome.
abstract: BACKGROUND
  The influence of the preservation solution used for in situ perfusion of the donor and pancreas storage on islet isolation has received little attention.
  
  
  METHODS
  In this prospective controlled trial, we compared the outcome of human islet isolation from pancreata perfused with University of Wisconsin (UW) solution or Celsior, an alternative colloid-free extracellular solution.
  
  
  RESULTS
  At the 1-year interim analysis, the viability and insulin secretion of islets isolated from donors perfused with UW (n=19) or Celsior (n=5) were identical. However, total islet recovery (IEQ) and isolation yield (IEQ/g) were 1.8-fold and 2.1-fold inferior in the Celsior group (P<0.05 vs. UW). Overall, 13 (68%) of islet preparations were effectively transplanted from the UW group vs. none from the Celsior group (P=0.01). The clinical study was discontinued and the causes of these differences were further explored in the pig (n=14). In contrast to UW, Celsior induced cell swelling and pancreas edema after only four hours of cold storage. These abnormalities were delayed when the donor was perfused with Solution de Conservation d'Organes et de Tissus (SCOT), an extracellular solution containing polyethylene glycol.
  
  
  CONCLUSIONS
  Our results suggest that colloid-free preservation solutions might be suboptimal for pancreas perfusion and cold storage prior to islet isolation and transplantation. Because pancreata are now frequently recovered for islet transplantation, preliminary experimental and clinical data about islet isolation should be obtained prior to the routine implementation of new preservation solutions for abdominal perfusion during multiorgan recovery.
authors.affiliation: Inserm U859, Diabetes Cell Therapy, Faculty of Medicine, Lille 2 University, Lille, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hubert
authors.forename: Valéry
authors.initials: V
authors.lastname: Gmyr
authors.forename: Laurent
authors.initials: L
authors.lastname: Arnalsteen
authors.forename: Thomas
authors.initials: T
authors.lastname: Jany
authors.forename: Frédéric
authors.initials: F
authors.lastname: Triponez
authors.forename: Robert
authors.initials: R
authors.lastname: Caiazzo
authors.forename: Brigitte
authors.initials: B
authors.lastname: Vandewalle
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Vantyghem
authors.forename: Julie
authors.initials: J
authors.lastname: Kerr-Conte
authors.forename: Francois
authors.initials: F
authors.lastname: Pattou
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D016022:Case-Control Studies; D003102:Colloids / Q000032:analysis; D004187:Disaccharides / Q000494:pharmacology; D004573:Electrolytes / Q000494:pharmacology; D005971:Glutamates / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006639:Histidine / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D016381:Islets of Langerhans Transplantation; D019520:Living Donors; D008353:Mannitol / Q000494:pharmacology; D008875:Middle Aged; D019188:Organ Preservation Solutions / Q000737:chemistry* / Q000494:pharmacology*; D011446:Prospective Studies; D011887:Raffinose / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: C088453:Celsior; D003102:Colloids; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose